


Role of histone acetyltransferases and histone deacetylases in the regulation of the inflammatory cascade.





Editorial Board

2010-2013

The World Journal of Gastrointestinal Pharmacology and Therapeutics Editorial Board consists of 188 members, representing a team of worldwide experts in gastrointestinal pharmacology and therapeutics research. They are from 36 countries, including Australia (6), Austria (2), Belgium (2), Brazil (1), Canada (7), China (19), Czech (1), Denmark (1), Egypt (1), Estonia (1), Finland (1), France (1), Germany (5), Greece (4), Hungary (1), India (6), Iran (1), Ireland (1), Israel (3), Italy (20), Japan (17), Lithuania (1), Netherlands (6), New Zealand (1), Norway (1), Pakistan (1), Saudi Arabia (2), Singapore (2), South Africa (1), South Korea (5), Spain (7), Sweden (1), Thailand (1), Turkey (4), United Kingdom (13), and United States (41).

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Antonio Picardi, *Rome*

Elham Rahme, *Québec*

Douglas Kevin Rex, *Indianapolis*

Angelo Zullo, *Rome*

GUEST EDITORIAL BOARD MEMBERS

Full-Young Chang, *Taoyuan*

Chia-Yen Dai, *Kaohsiung*

Jiang-Huei Jeng, *Taipei*

Wun-Chang Ko, *Taipei*

Hwai Jeng Lin, *Changhua*

Tzu-Ming Pan, *Taipei*

Bor-Shyang Sheu, *Tainan*

Being-Sun Wung, *Chiayi*

MEMBERS OF THE EDITORIAL BOARD



Australia

Thomas J Borody, *Sydney*

Eline S Klaassens, *Queensland*

Ian Lawrance, *Fremantle*

A Mikocka-Walus, *Melbourne*

Tim Murphy, *Adelaide*

Neville D Yeomans, *Sydney*



Austria

Martin Brunner, *Vienna*

Michael Trauner, *Graz*



Belgium

Monika Schöller-Gyüre, *Mechelen*

Kristin Verbeke, *Alsemberg*



Brazil

Andréia Buffon, *Porto Alegre*



Canada

Brian Bressler, *Vancouver*

Grigorios I Leontiadis, *Hamilton*

Sharon Marsh, *Quebec*

Jean Sévigny, *Quebec*

Martin A Storr, *Alberta*

John T Weber, *Newfoundland*



China

Zhi-Li Huang, *Shanghai*

Bo Li, *Beijing*

Duo Li, *Shanghai*

Xue-Ying Sun, *Heilongjiang*

Ming-Fu Wang, *Hong Kong*

Rui-An Xu, *Xiamen*

Thomas Yau, *Hong Kong*

Win-Nei Yeo, *Hong Kong*

Long Yu, *Guangzhou*

Jian-Ping Yuan, *Guangzhou*

Man-Fung Yuen, *Hong Kong*



Czech

Rene Kizek, *Brno*



Denmark

Ole Haagen Nielsen, *Herlev*



Egypt

Ahmed O Abdel-Zaher, *Assiut*



Estonia

Riin Tamm, *Tartu*



Finland

Riitta Korpela, *Helsinki*



France

Frederic Batteux, *Paris*



Germany

Anton Gillissen, *Muenster*

Joachim Labenz, *Siegen*

Florian Lang, *Tübingen*

Klaus Mönkemüller, *Magdeburg*

Gerhard Treiber, *Balingen*

**Greece**

Moses Elisaf, *Ioannina*
Ioannis E Koutroubakis, *Crete*
Spilios Manolakopoulos, *Athens*
George Papatheodoridis, *Athens*

**Hungary**

Bela Molnar, *Budapest*

**India**

Mohammad S Khuroo, *Kashmir*
Mohandas K Mallath, *Mumbai*
Asish K Mukhopadhyay, *Kolkata*
Shiv Kumar Sarin, *New Delhi*
Sonu Sundd Singh, *Haryana*
Asna Urooj, *Mysore*

**Iran**

Amir M Mortazavian, *Tehran*

**Ireland**

Zaid Heetun, *Kilkenny*

**Israel**

Rami Eliakim, *Haifa*
Simon Bar Meir, *Hashomer*
Haim S Odes, *Beer Sheva*

**Italy**

Pietro Andreone, *Bologna*
Bruno Annibale, *Roma*
Giuseppe Brisinda, *Roma*
Renzo Caprilli, *Rome*
Carolina Ciacci, *Naples*
Roberto De Giorgio, *Bologna*
Alessandro Granito, *Bologna*
Pietro Invernizzi, *Rozzano*
Mariano Malaguarnera, *Catania*
Gianpiero Manes, *Milan*
Massimo C Mauri, *Milan*
Massimo Montalto, *Rome*
Giovanni Monteleone, *Rome*
Gerardo Nardone, *Napoli*
Fabio Pace, *Milan*
Rita Rezzani, *Brescia*
Carmelo Scarpignato, *Parma*
Maurizio Vecchi, *Milan*

**Japan**

Akira Andoh, *Otsu*
Norihiro Furusyo, *Fukuoka*

Susumu Ito, *Okinawa*
Satoru Kakizaki, *Gunma*
Terumi Kamisawa, *Tokyo*
Takuma Kato, *Tsu*
Takashi Kawai, *Tokyo*
Tatsuya Matsura, *Yonago*
Teruo Murakami, *Hiroshima*
Yuji Naito, *Kyoto*
Katsuyuki Nakajima, *Maebashi Gunma*
Hiroshi Nakase, *Kyoto*
Tomohiko Shimatani, *Hiroshima*
Takato Ueno, *Kurume*
Kenji Watanabe, *Osaka*
Takayuki Yamamoto, *Yokkaichi*
Norimasa Yoshida, *Kyoto*

**Lithuania**

Laimas Jonaitis, *Kaunas*

**Netherlands**

Judith E Baars, *Rotterdam*
Albert J Bredenoord, *Nieuwegein*
NKH de Boer, *Amsterdam*
PJF de Jonge, *Rotterdam*
Wouter J de Jonge, *Amsterdam*
Godefridus J Peters, *Amsterdam*

**New Zealand**

Maxim Petrov, *Auckland*

**Norway**

Reidar Fossmark, *Trondheim*

**Pakistan**

Furqaan Ahmed, *Karachi*

**Saudi Arabia**

Moamen S Refat, *Taif*
Shahab Uddin, *Riyadh*

**Singapore**

Khek-Yu Ho, *Singapore*
Kok-Yuen Ho, *Singapore*

**South Africa**

Christoffel J van Rensburg, *Cape Town*

**South Korea**

Chong-Su Cho, *Seoul*

Nayoung Kim, *Seongnam*
Kwan Sik Lee, *Seoul*
Ji-Young Park, *Seoul*
Young-Joon Surh, *Seoul*

**Spain**

Matias A Avila, *Pamplona*
Maria C Collado, *Paterna*
CM Fernandez-Rodriguez, *Madrid*
Jose JG Marin, *Salamanca*
Antonio Ruiz Medina, *Jaén*
Victor M Victor, *Valencia*
Maria D Yago, *Granada*

**Sweden**

Curt Tysk, *Örebro*

**Thailand**

Abhasnee Sobhonslidsuk, *Bangkok*

**Turkey**

Fusun Acarturk, *Ankara*
Hayrullah Derici, *Balıkesir*
Mukaddes Eşrefoğlu, *Malatya*
Ilker Tasci, *Ankara*

**United Kingdom**

Nadeem A Afzal, *Hampshire*
Qasim Aziz, *London*
Barbara Braden, *Oxford*
Susan J Duthie, *Aberdeen*
AV Emmanuel, *London*
Jin-Yong Kang, *London*
Mariusz Madalinski, *Ipswich*
John F Mayberry, *Leicester*
Chuka Uche Nwokolo, *Coventry*
Ajith K Siriwardena, *Manchester*
HH Tsai, *E Yorks*
Konstantinos Tziomalos, *London*
Craig LC Williams, *Glasgow*

**United States**

Kondala R Atkuri, *Stanford*
James M Becker, *Boston*
Qiang Cai, *Atlanta*
Liang Cheng, *Indianapolis*
Joseph John Cullen, *Iowa*
Brian J Day, *Denver*
Douglas A Drossman, *Chapel Hill*
Eli D Ehrenpreis, *Highland Park*
Bing-Liang Fang, *Houston*
Ronnie Fass, *Tucson*
S Hossein Fatem, *Minneapolis*
Linda A Feagins, *Dallas*

Lori Fischbach, *Fort Worth*
M Eric Gershwin, *Davis*
Hendrik Heinz, *Akron*
Tiberiu Herscovici, *Tucson*
Peng Huang, *Houston*
William Jeffrey Hurst, *Hershey*
Vik Khoshoo, *Marrero*
Tammy L Kindel, *Cincinnati*
Lorenzo Leggio, *Providence*
Allen W Mangel, *Research Triangle Park*
Michael F Olive, *Charleston*
Keith M Olsen, *Omaha*
Virendra N Pandey, *Newark*
Narasimham L Parinandi, *Columbus*
Paul J Pockros, *La Jolla*
Suofu Qin, *Irvine*
P Hemachandra Reddy, *Oregon*
Randolph E Regal, *Ann Arbor*
Jean-François Rossignol, *Tampa*
Leonard P Rybak, *Springfield*
George Sachs, *Los Angeles*
Bo Shen, *Cleveland*
Biographical Sketch, *Hershey*
Shi-Yong Sun, *Atlanta*
Kenneth J Vega, *Jacksonville*
Yu-Jui Yvonne Wan, *Kansas*
Jian-Min Yuan, *Minneapolis*
Jian-Ying Zhang, *El Paso*



TOPIC HIGHLIGHT

75

Protein phosphatases and chromatin modifying complexes in the inflammatory cascade in acute pancreatitis

Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, López-Rodas G, Sastre J

Contents

World Journal of Gastrointestinal Pharmacology and Therapeutics

Volume 1 Number 3 June 6, 2010

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Gastrointestinal Pharmacology and Therapeutics*

APPENDIX I Meetings
I-IV Instructions to authors

ABOUT COVER Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, López-Rodas G, Sastre J. Protein phosphatases and chromatin modifying complexes in the inflammatory cascade in acute pancreatitis.
World J Gastrointest Pharmacol Ther 2010; 1(3): 75-80
<http://www.wjgnet.com/2150-5349/full/v1/i3/75.htm>

AIM AND SCOPE *World Journal of Gastrointestinal Pharmacology and Therapeutics* (*World J Gastrointest Pharmacol Ther*, *WJGPT*, online ISSN 2150-5349, DOI: 10.4292), is a bimonthly, open-access, peer-reviewed journal supported by an editorial board of 188 experts in gastrointestinal surgery from 36 countries.
The major task of *WJGPT* is to rapidly report the most recent results in basic and clinical research on gastrointestinal pharmacology and therapeutics, including the effects of drugs on the gastrointestinal, pancreatic and hepatobiliary systems, particularly with relevance to clinical practice. *WJGPT* accepts papers on the following aspects related to gastroenterology or hepatology: (1) Clinical pharmacological research articles on specific drugs, concerning with pharmacodynamics, pharmacokinetics, toxicology, clinical trial, drug reactions, drug metabolism and adverse reaction monitoring, *etc*; (2) Research progress of clinical pharmacology; (3) Introduction and evaluation of new drugs; (4) Experiences and problems in applied therapeutics; (5) Research and introductions of methodology in clinical pharmacology; and (6) Guidelines of clinical trial. Specifically, this journal welcome research and review articles associated with both Western medicine and Chinese herbs as well as their combinations in basic and clinical application.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Na Liu
Responsible Electronic Editor: Chuan Yang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Jin-Lei Wang
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL

World Journal of Gastrointestinal Pharmacology and Therapeutics

LAUNCH DATE

February 6, 2010

SPONSOR

Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: 0086-10-8538-1892
Fax: 0086-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

EDITING

Editorial Board of *World Journal of Gastrointestinal Pharmacology and Therapeutics*,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: 0086-10-8538-1891
Fax: 0086-10-8538-1893
E-mail: wjgpt@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING

Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China

Telephone: 0086-10-8538-1892
Fax: 0086-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION

Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: 0086-10-8538-1892
Fax: 0086-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

ONLINE SUBSCRIPTION

One-Year Price 108.00 USD

PUBLICATION DATE

June 6, 2010

CSSN

ISSN 2150-5349 (online)

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Antonio Picardi, *Rome*
Elham Rahme, *Québec*
Douglas Kevin Rex, *Indianapolis*
Angelo Zullo, *Rome*

EDITORIAL OFFICE

Jin-Lei Wang, Director
World Journal of Gastrointestinal Pharmacology and Therapeutics
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: 0086-10-8538-1891
Fax: 0086-10-8538-1893
E-mail: wjgpt@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT

© 2010 Baishideng. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of Baishideng. Author are required to grant *World Journal of Gastrointestinal Pharmacology and Therapeutics* an exclusive license to publish.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/2150-5349/g_info_20100315084234.htm. If you do not have web access please contact the editorial office.

ONLINE SUBMISSION

<http://www.wjgnet.com/2150-5349/office>

Maria D Yago, PhD, Series Editor

Protein phosphatases and chromatin modifying complexes in the inflammatory cascade in acute pancreatitis

Javier Escobar, Javier Pereda, Alessandro Arduini, Juan Sandoval, Luis Sabater, Luis Aparisi, Gerardo López-Rodas, Juan Sastre

Javier Escobar, Javier Pereda, Alessandro Arduini, Juan Sastre, Department of Physiology, University of Valencia, 46100 Burjassot (Valencia), Spain

Juan Sandoval, Gerardo López-Rodas, Department of Biochemistry & Molecular Biology, University of Valencia, 46100 Burjassot (Valencia), Spain

Luis Sabater, Department of Surgery, University Clinic Hospital, 46010 Valencia, Spain

Luis Aparisi, Laboratory of Pancreatic Function, University Clinic Hospital, 46010 Valencia, Spain

Author contributions: The item on the pathophysiology of pancreatitis was written by Sastre J, Sabater L and Aparisi L; items on chromatin modifying complexes were written by López-Rodas G, Sandoval J and Sastre J; the item on protein phosphatases was written by Escobar J, Pereda J, Arduini A and Sastre J; the item on potential therapy was written by Sastre J; the figure was designed by Escobar J and Pereda J with the supervision of López-Rodas G and Sastre J.

Supported by Grants SAF2006-06963, SAF2009-09500 and Consolider CSD-2007-00020 to Sastre J; BFU2007-63120 and CSD2006-49 to López-Rodas G

Correspondence to: Juan Sastre, Professor, Department of Physiology, School of Pharmacy, University of Valencia, Avda. Vicente Andrés Estellés s/n, 46100 Burjassot (Valencia), Spain. juan.sastre@uv.es

Telephone: +34-96-3543815 Fax: +34-96-3543395

Received: November 25, 2009 Revised: February 10, 2010

Accepted: February 17, 2010

Published online: June 6, 2010

modifying complexes and chromatin remodeling. Among the different families of histone acetyltransferases, the p300/CBP family seems to be particularly associated with the inflammatory process. cAMP activates gene expression *via* the cAMP-responsive element (CRE) and the transcription factor CRE-binding protein (CREB). CREB can be phosphorylated and activated by different kinases, such as protein kinase A and MAPK, and then it recruits the histone acetyltransferase co-activator CREB-binding protein (CBP) and its homologue p300. The recruitment of CBP/p300 and changes in the level of histone acetylation are required for transcription activation. Transcriptional repression is also a dynamic and essential mechanism of down-regulation of genes for resolution of inflammation, which seems to be mediated mainly by protein phosphatases (PP1, PP2A and MKP1) and histone deacetylases (HDACs). Class II HDACs are key transcriptional regulators whose activities are controlled *via* phosphorylation-dependent nucleo/cytoplasmic shuttling. PP2A is responsible for dephosphorylation of class II HDACs, triggering nuclear localization and repression of target genes, whereas phosphorylation triggers cytoplasmic localization leading to activation of target genes. The potential benefit from treatment with phosphodiesterase inhibitors and histone deacetylase inhibitors is discussed.

© 2010 Baishideng. All rights reserved.

Key words: Dual specificity protein phosphatases; Acute pancreatitis; Phosphodiesterase inhibitors; Cytokines; Histone acetylation; Pentoxifylline; PP2A; Serine/threonine protein phosphatases

Peer reviewer: Ilker Tasci, MD, Associate Professor, Department of Internal Medicine, Gulhane School of Medicine, Etlik 06018, Ankara, Turkey

Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, López-Rodas G, Sastre J. Protein phosphatases and chromatin modifying complexes in the inflammatory cascade in acute

Abstract

Acute pancreatitis is an inflammation of the pancreas that may lead to systemic inflammatory response syndrome and death due to multiple organ failure. Acinar cells, together with leukocytes, trigger the inflammatory cascade in response to local damage of the pancreas. Amplification of the inflammatory cascade requires up-regulation of pro-inflammatory cytokines and this process is mediated not only by nuclear factor κ B but also by chromatin

pancreatitis. *World J Gastrointest Pharmacol Ther* 2010; 1(3): 75-80 Available from: URL: <http://www.wjgnet.com/2150-5349/full/v1/i3/75.htm> DOI: <http://dx.doi.org/10.4292/wjgpt.v1.i3.75>

PATHOPHYSIOLOGY OF ACUTE PANCREATITIS

Acute pancreatitis (AP) is an inflammation of the pancreas that often leads to systemic inflammatory response and complications. The mortality rate is approximately 5% but it rises to 17% in cases of severe AP^[1]. Mortality in AP is due to multiple organ failure induced by the systemic inflammatory response.

The major causes of the disease are alcohol and gallstones. Nevertheless, the precise mechanisms triggered by the etiological factors to induce tissue injury and an attack of AP are still a matter of debate. An early event in AP is the intrapancreatic activation of trypsinogen and other zymogen enzymes^[2]. However, pancreatic digestive enzymes are not responsible for the conversion of a local inflammatory process into a systemic inflammatory response. Numerous inflammatory mediators, such as pro-inflammatory cytokines, chemokines, free radicals, Ca^{2+} , platelet activating factor, and adenosine, have been involved in the pathogenesis of AP and its derived systemic inflammatory response^[3-5]. Therefore, AP should be considered another pathological condition together with sepsis, trauma, burns and surgery, which may lead to the systemic inflammatory response syndrome and multiple organ failure.

AP is characterized by interstitial edema and inflammatory infiltrate of macrophages and neutrophils. Nevertheless, acinar cells also behave as inflammatory cells producing and releasing cytokines, chemokines and adhesion molecules^[3,6,7]. Hence, acinar cells together with leukocytes trigger the inflammatory cascade in response to local damage of the pancreas. Tumor necrosis factor α (TNF- α) and interleukin 1- β initiate and propagate almost all the consequences of the systemic inflammatory response in AP^[8]. Interleukin-6 (IL-6) is a mediator of the acute-phase response and also a marker of severity of AP^[9]. The role of cytokines in AP has already been extensively reviewed^[4,5].

Amplification of the inflammatory cascade requires up-regulation of pro-inflammatory cytokines and this process is mediated mainly by nuclear factor κ B (NF- κ B). Elucidation of the role of chromatin modifying complexes and chromatin remodeling in the inflammatory cascade is currently underway and is the focus of the present review.

CHROMATIN MODIFYING COMPLEXES

Nucleosomes, the basic units of eukaryotic chromatin, consist of a histone core with two copies of each core histones H2A, H2B, H3 and H4 and approximately 147 bp of DNA wrapped around the histone octamers. The nucleosomes are structured along the DNA polymer as

“beads on a string”, further compacted in the presence of the linker histone H1 to 30 nm solenoid, and finally to the metaphasic chromosome. Nevertheless, the chromatin structure creates an obstacle for the transcriptional machinery, as transcription factors must gain access to the compact DNA template. In order to bypass the transcriptional constrictions, cells have organized the binding of transcriptional activators that target chromatin modifier enzymes to the promoters allowing changes in the chromatin structure and accessibility.

The chromatin modifier complexes covalently modify the histones, either in the histone tails (acetylation, phosphorylation and methylation) or outside the histone tails (ubiquitylation, glycosylation, SUMOylation and ADP-ribosylation), changing the overall charge or hydrophobicity of histones, and modifying the chromatin structure^[10,11]. This review focuses on the dynamics of histone acetylation in acute inflammation, particularly in AP.

The combined action of histone acetyltransferases (HAT) and histone deacetylases (HDAC) maintains, through a subtle balance, the steady-state levels of histone acetylation. HAT are enzymes that catalyze the transfer of an acetyl group from acetyl-coenzyme A to the ϵ -amino groups of conserved lysine residues mainly in histone N-terminal tails. This process is generally linked to transcriptional activity^[12] as the neutralization of the basic charge of the histone tails favours the transcription process^[13]. On the other hand, HDAC are enzymes that remove acetyl groups from lysine residues of histones, and other non-histone proteins, and reverse the action of HAT^[14].

Among the different families of HAT^[15,16], the p300/CBP family seems to be particularly associated with the inflammatory process. It comprises the highly related p300 and CBP proteins that have a bromo-domain and three cysteine/histidine rich domains that serve as protein-protein interacting domains. Members of this family are co-activators for multiple transcription factors and they can also associate with other acetyltransferases, showing that multiple HAT enzymes can be recruited to the promoter to act synergistically during gene activation.

HDACs have been classified into four different subfamilies (I, II, III and IV). Class I and II HDACs contain a zinc cation in the catalytic site and they are sensitive to the inhibitor trichostatin A^[17], whereas class III HDACs are insensitive to TSA treatment and require the coenzyme NAD^+ as a cofactor^[18]. HDAC11 is so far the only class IV member. HDACs have to be localized in the nucleus to be active towards histones, but some of them (class II and III HDACs) can also be found in the cytosol. Nuclear targeting of HDACs takes place by a nuclear localisation signal or by interacting with other proteins that translocate them to the nucleus^[19]. For instance, HDAC1, HDAC2 and HDAC3 are exclusively nuclear, while HDAC 4, -5 and -7 are able to shuttle in and out of the nucleus in response to cellular stimuli^[20,21].

The lysine and arginine residues of histones can be further modified by methylation. Histone methylation has been associated with both transcriptional activation




Figure 1 Role of histone acetyltransferases (HATs) and histone deacetylases (HDACs) in the regulation of the inflammatory cascade. HATs and HDACs play central roles, together other chromatin modifying complexes, such as histone methyltransferases, DNA methyltransferases, methyl DNA binding proteins, and heterochromatin proteins, in the activation and attenuation phases of the inflammatory cascade.

and repression depending on the methylated residue, the degree of methylation and on the interplay with other modifications^[11].

Histone H3 may be subject to MAP kinase-mediated phosphorylation in serine 10 and 28 by mitogen- and stress-activated protein kinases MSK1 and MSK2, which trigger transcription of immediate-early genes^[22]. Other histones may also be phosphorylated leading to transcriptional activation.

TRANSCRIPTION ACTIVATION IN THE INFLAMMATORY CASCADE IS MEDIATED BY HISTONE ACETYLATION AND METHYLATION

cAMP activates gene expression *via* the cAMP-responsive element (CRE) and the transcription factor CRE-binding protein (CREB). CREB can be phosphorylated and activated by different kinases, such as protein kinase A, MAPK and CaMKIV^[23], and then it recruits the HAT's co-activator CREB-binding protein (CBP) and its homologue p300. The recruitment of CBP/p300 and histone acetylation is required for transcription activation^[24]. CREB activation *via* phosphorylation and subsequent CREB-mediated gene expression seem to play an important role in the inflammatory cascade (Figure 1). Thus, CREB phosphorylation by protein kinase C- θ and DNA-CREB binding are required for up-regulation of IL-2 in T-cells^[25].

CBP and p300 are co-activators of (NF- κ B). Accordingly, NF- κ B-induced gene transcription is mediated by histone acetylation. NF- κ B is the major mediator of TNF- α -induced IL-6 gene expression, which requires CBP/p300 histone acetyltransferase activity^[26]. Similar findings were reported for other NF- κ B-driven promoters, such as those

of IL-8 and endothelial leukocyte adhesion molecule. p300 is also required for transcriptional activation of cyclooxygenase-2 (COX-2) by interleukin-1 β or lipopolysaccharide in macrophages^[27].

The E-selectin gene is rapidly and transiently expressed by endothelial cells upon inflammation and it promotes binding and extravasation of leukocytes from the bloodstream. TNF- α induces NF- κ B (p65) binding together with histone hyperacetylation *via* p300/CBP in the E-selectin gene in endothelial cells^[28].

Histone H3 acetylation (H3K9 and H3K14), as well as histone H3 methylation (H3R17), are regulated at the promoters of NF- κ B-target genes in a CBP/p300 dependent manner^[29]. Coactivator-associated arginine methyltransferase-1 (CARM1) is recruited to NF- κ B-target promoters and participates in NF- κ B-mediated transcription through H3 methylation at arginine 17 (H3R17)^[29].

STAT 3 is the major signal transducer of IL-6 and hence it mediates acute phase protein induction. IL-6-induced angiotensinogen expression is mediated by association of STAT3 with p300/CBP to trigger histone acetylation and chromatin remodeling^[30]. Recently, it has been confirmed that STAT3 transactivates its target genes through recruitment of CBP/p300 co-activators^[31].

SHP-1 phosphatase is a key negative regulator of cell signaling. STAT3, DNA methyltransferase 1 and HDAC 1 form complexes that bind to the promoter of SHP-1^[32]. Thus, STAT3 may induce methylation of this promoter and epigenetic silencing of SHP-1^[32].

ATTENUATION OF THE INFLAMMATORY RESPONSE BY HDAC AND PROTEIN PHOSPHATASES

Transcriptional repression is also a dynamic and essential mechanism of down-regulation of genes for resolution of inflammation. Chromatin modifying complexes act coordinately to regulate cAMP-dependent transcription during the activation phase but also during the attenuation phase. As pointed out by Canetti *et al.*^[33], cAMP-mediated transcription exhibits burst-attenuation kinetics in parallel with PKA-dependent phosphorylation and subsequent PP1-mediated dephosphorylation of CREB. PP1, but not PP2A, blocks CRE-regulated gene expression and transcriptional attenuation of cAMP-induced gene expression requires CREB dephosphorylation by PP1^[34]. PP1 is targeted to CREB by binding with class-I HDACs, such as HDAC1 and HDAC8, promoting CREB inactivation by dephosphorylation during pre-stimulus and attenuation phases of the cAMP response^[23,33]. Consequently, PP1 and class-I HDACs regulate the duration of CREB-mediated gene transcription (Figure 1). Nevertheless, nuclear PP2A might also be involved in the dephosphorylation of CREB^[35].

Attenuation of cAMP-dependent transcription also involves other proteins, such as CRE modulator (CREM)- α , which is a ubiquitously expressed transcription factor respon-

sible for the termination of IL-2 expression in T cells^[36]. CREM down-regulates the expression of IL-2 *via* recruitment of HDAC1 and reduces acetylation of histones^[36].

PP2A comprises a family of holoenzyme complexes with diverse biological activities, which mainly depend on individual regulatory subunits. PP2A holoenzymes may form complexes with IKK and negatively regulate NF- κ B transcriptional activity^[37]. Some PP2A regulatory subunits, such as PR55 γ and PR55 δ , are inhibitors of JNK and c-SRC^[38]. The PP2A heterotrimeric complex formed by the PR65 A subunit, the catalytic subunit (PP2Ac), and G5PR as a regulatory subunit exhibits phosphatase activity on histone H1^[39].

Class II HDACs are key transcriptional regulators whose activities are controlled *via* phosphorylation-dependent nucleo-cytoplasmic shuttling^[40]. PP2A is responsible for dephosphorylation of class II HDACs triggering nuclear localization and repression of target genes, whereas phosphorylation triggers cytoplasmic localization leading to activation of target genes^[40,41]. Nitric oxide (NO) induces the formation of a complex between HDAC4, HDAC5, and PP2A that triggers HDAC4 and HDAC5 nuclear shuttling^[42]. Thus, NO enhances HDAC activity inhibiting serum-induced histone acetylation in endothelial cells^[42].

HDAC3 is a member of class I HDACs involved in the regulation of gene expression that is activated through phosphorylation^[43]. HDAC3 seems to act as a scaffold protein for PP2A to dephosphorylate STAT3 and promote inactivation of the STAT3-mediated signaling pathway^[44]. In addition, HDAC3 forms a complex with serine/threonine protein phosphatase 4 and its activity is inversely proportional to the cellular levels of this phosphatase^[43].

In addition, HDACs down-regulate other inflammatory mediators, such as E-selectin, in the attenuation of the inflammatory cascade. Thus, repression of E-selectin expression is associated with recruitment of HDAC^[28].

Dual specificity protein phosphatases, such as MAPK phosphatase-1 (MKP-1) and MKPM-M, also play an important role in the attenuation of the inflammatory cascade, mainly through inactivation of MAP kinases. MKP1 up-regulation is involved in the attenuating response to lipopolysaccharide (LPS) and its induction requires p38 activity^[45]. Histone H3 may be phosphorylated by signal transduction pathways and is a novel substrate of MAPK phosphatase-1 (MKP-1)^[46].

MKPM-M is rapidly induced by LPS in macrophages and leads to JNK inactivation and decreased TNF- α secretion. LPS causes acetylation of histones H3 and H4 at the promoter of the dual specificity phosphatase MKP-M gene and this effect seems to be mediated by the CREB/CBP pathway^[47].

Further studies are needed to elucidate the role of protein phosphatases and HDACs in severe AP in comparison with the mild form of the disease. Indeed, the mechanisms responsible for resolution of inflammation in AP should be identified in order to properly restrain the evolution of the disease.

POTENTIAL BENEFIT FROM TREATMENT WITH PHOSPHODIESTERASE INHIBITORS AND HDAC INHIBITORS IN AP

So far, no specific effective treatment for AP has been reported in clinical trials. Thus the search for novel therapeutic strategies is still focused on experimental models. Phosphodiesterase inhibitors, such as pentoxifylline and rolipram, ameliorate AP in rodents^[48-50]. Their beneficial effects seem to be mediated by inhibition of leukocyte activation and migration reducing the up-regulation of TNF- α and IL-6^[49,51]. Pentoxifylline exhibits marked anti-inflammatory properties mainly ascribed to the blockade of ERK phosphorylation and inhibition of TNF- α production^[48,49]. We have recently demonstrated that it prevents the remarkable loss of serine/threonine phosphatase PP2A activity in pancreas early in the course of AP^[52]. This effect was associated with maintenance of cAMP levels, reduced recruitment of histone acetyltransferases and abrogation of up-regulation of pro-inflammatory genes^[52]. Consequently, phosphodiesterase inhibitors seem to be beneficial early in the course of AP by down-regulation of the ERK-pathway preventing histone acetylation and the resulting up-regulation of inflammatory mediators.

The action of phosphodiesterase inhibitors may also be mediated by stimulation of dual specificity phosphatases. Dipyridamole is a non-selective phosphodiesterase inhibitor that exerts its anti-inflammatory effect *via* transient activation of MKP-1, which dephosphorylates and inactivates MAPK and particularly p38^[53]. Dipyridamole inhibits the NF- κ B signaling pathway blocking up-regulation of IL-6, monocyte chemoattractant protein-1, inducible NO synthase and COX-2 in LPS-activated macrophages^[53].

The therapeutic window for treatment with phosphodiesterase inhibitors should be limited to the very early stage of the disease or to prevent the risk of AP induced by endoscopic retrograde cholangiopancreatography. Since an increase in cAMP levels might trigger the PKA/CREB/CBP pathway involved in cytokine up-regulation, the administration of phosphodiesterase inhibitors could not be beneficial when the inflammatory cascade is already ongoing.

Taken into account the involvement of HATs in the up-regulation of pro-inflammatory cytokines and the role of HDACs in the attenuation of inflammation, it seems paradoxical that HDAC inhibitors may exhibit anti-inflammatory properties. Nevertheless, it has been recently reported that histone deacetylase inhibitors reduce inflammation and mortality in mice treated with LPS by blockade of MAPK signaling due to MKP-1 acetylation^[54]. Acetylation of MKP-1 is mediated by p300 upon LPS stimulation and it increases its phosphatase activity inhibiting innate immune signaling^[54].

However, in the case of AP, the therapeutic window for HDAC inhibitors should be limited to a late stage of the disease in order to promote attenuation of the inflammatory response because they may enhance CREB activity during the burst phase. Nevertheless, further studies are needed

to establish the therapeutic windows of phosphodiesterase inhibitors and HDAC inhibitors.

CONCLUSION

In conclusion, amplification of the inflammatory cascade requires up-regulation of pro-inflammatory cytokines and this process is mediated not only by NF- κ B but also by chromatin modifying complexes and chromatin remodeling. Transcription activation in the inflammatory cascade is mediated by histone acetylation through recruitment of HAT, particularly CBP and p300. On the other hand, attenuation of the inflammatory response is also a dynamic mechanism that involves protein phosphatases, especially serine threonine phosphatases PP1 and PP2A, as well as recruitment of HDAC. Phosphodiesterase inhibitors have exhibited beneficial effects in the treatment of AP by preventing histone acetylation and the loss of PP2A activity. Inhibitors of HDAC are also proposed as potential therapy for AP. Nevertheless, the therapeutic windows of these therapeutic agents should be established.

REFERENCES

- Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. *Gastroenterology* 2007; **133**: 1056.e1-1056.e25
- Grady T, Saluja A, Kaiser A, Steer M. Edema and intrapancreatic trypsinogen activation precede glutathione depletion during caerulein pancreatitis. *Am J Physiol* 1996; **271**: G20-G26
- Grady T, Liang P, Ernst SA, Logsdon CD. Chemokine gene expression in rat pancreatic acinar cells is an early event associated with acute pancreatitis. *Gastroenterology* 1997; **113**: 1966-1975
- Pereda J, Sabater L, Aparisi L, Escobar J, Sandoval J, Viña J, López-Rodas G, Sastre J. Interaction between cytokines and oxidative stress in acute pancreatitis. *Curr Med Chem* 2006; **13**: 2775-2787
- Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, López-Rodas G, Sastre J. Cross-talk between oxidative stress and pro-inflammatory cytokines in acute pancreatitis: a key role for protein phosphatases. *Curr Pharm Des* 2009; **15**: 3027-3042
- Gukovskaya AS, Gukovsky I, Zaninovic V, Song M, Sandoval D, Gukovsky S, Pandol SJ. Pancreatic acinar cells produce, release, and respond to tumor necrosis factor- α . Role in regulating cell death and pancreatitis. *J Clin Invest* 1997; **100**: 1853-1862
- De Dios I, Ramudo L, Alonso JR, Recio JS, Garcia-Montero AC, Manso MA. CD45 expression on rat acinar cells: involvement in pro-inflammatory cytokine production. *FEBS Lett* 2005; **579**: 6355-6360
- Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. *Am J Surg* 1998; **175**: 76-83
- Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, Rückauer K, Andreesen R, Farthmann EH, Schölmerich J. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. *Gastroenterology* 1991; **101**: 782-785
- Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. *Annu Rev Biochem* 2006; **75**: 243-269
- Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. *Annu Rev Biochem* 2007; **76**: 75-100
- Cheung WL, Briggs SD, Allis CD. Acetylation and chromosomal functions. *Curr Opin Cell Biol* 2000; **12**: 326-333
- Roth SY, Denu JM, Allis CD. Histone acetyltransferases. *Annu Rev Biochem* 2001; **70**: 81-120
- Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. *Eur J Cancer* 2005; **41**: 2381-2402
- Marmorstein R, Roth SY. Histone acetyltransferases: function, structure, and catalysis. *Curr Opin Genet Dev* 2001; **11**: 155-161
- Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. *Nat Rev Mol Cell Biol* 2007; **8**: 284-295
- Tsai SC, Seto E. Regulation of histone deacetylase 2 by protein kinase CK2. *J Biol Chem* 2002; **277**: 31826-31833
- Sengupta N, Seto E. Regulation of histone deacetylase activities. *J Cell Biochem* 2004; **93**: 57-67
- de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. *Biochem J* 2003; **370**: 737-749
- Kao HY, Verdel A, Tsai CC, Simon C, Juguilon H, Khochbin S. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. *J Biol Chem* 2001; **276**: 47496-47507
- Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. *Proc Natl Acad Sci USA* 2000; **97**: 7835-7840
- Clayton AL, Mahadevan LC. MAP kinase-mediated phosphorylation of histone H3 and inducible gene regulation. *FEBS Lett* 2003; **546**: 51-58
- Gao J, Siddoway B, Huang Q, Xia H. Inactivation of CREB mediated gene transcription by HDAC8 bound protein phosphatase. *Biochem Biophys Res Commun* 2009; **379**: 1-5
- Yuan LW, Gambée JE. Histone acetylation by p300 is involved in CREB-mediated transcription on chromatin. *Biochim Biophys Acta* 2001; **1541**: 161-169
- Solomou EE, Juang YT, Tsokos GC. Protein kinase C- θ participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the -180 site of the IL-2 promoter in normal human T lymphocytes. *J Immunol* 2001; **166**: 5665-5674
- Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. *J Biol Chem* 1999; **274**: 32091-32098
- Deng WG, Zhu Y, Wu KK. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. *Blood* 2004; **103**: 2135-2142
- Edelstein LC, Pan A, Collins T. Chromatin modification and the endothelial-specific activation of the E-selectin gene. *J Biol Chem* 2005; **280**: 11192-11202
- Miao F, Li S, Chavez V, Lanting L, Natarajan R. Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. *Mol Endocrinol* 2006; **20**: 1562-1573
- Ray S, Sherman CT, Lu M, Brasier AR. Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity. *Mol Endocrinol* 2002; **16**: 824-836
- Cvijic H, Bauer K, Löffler D, Pfeifer G, Blumert C, Kretzschmar AK, Henze C, Brocke-Heidrich K, Horn F. Co-activator SRC-1 is dispensable for transcriptional control by STAT3. *Biochem J* 2009; **420**: 123-132
- Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. *Proc Natl Acad Sci USA* 2005; **102**: 6948-6953
- Canetti G, Morantte I, Guzmán E, Asahara H, Herzig S, Anderson SD, Yates JR 3rd, Montminy M. Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. *Nat Struct Biol* 2003; **10**: 175-181
- Hagiwara M, Alberts A, Brindle P, Meinkoth J, Feramisco J, Deng T, Karin M, Shenolikar S, Montminy M. Transcriptional

- attenuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB. *Cell* 1992; **70**: 105-113
- 35 **Wadzinski BE**, Wheat WH, Jaspers S, Peruski LF Jr, Lickteig RL, Johnson GL, Klemm DJ. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. *Mol Cell Biol* 1993; **13**: 2822-2834
- 36 **Tenbrock K**, Juang YT, Leukert N, Roth J, Tsokos GC. The transcriptional repressor cAMP response element modulator alpha interacts with histone deacetylase 1 to repress promoter activity. *J Immunol* 2006; **177**: 6159-6164
- 37 **Li S**, Wang L, Berman MA, Zhang Y, Dorf ME. RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. *Mol Cell* 2006; **24**: 497-509
- 38 **Eichhorn PJ**, Creighton MP, Wilhelmsen K, van Dam H, Bernards R. A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. *PLoS Genet* 2007; **3**: e218
- 39 **Kono Y**, Maeda K, Kuwahara K, Yamamoto H, Miyamoto E, Yonezawa K, Takagi K, Sakaguchi N. MCM3-binding GANP DNA-primase is associated with a novel phosphatase component G5PR. *Genes Cells* 2002; **7**: 821-834
- 40 **Martin M**, Potente M, Janssens V, Vertommen D, Twizere JC, Rider MH, Goris J, Dimmeler S, Kettmann R, Dequiedt F. Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. *Proc Natl Acad Sci USA* 2008; **105**: 4727-4732
- 41 **Paroni G**, Cernotta N, Dello Russo C, Gallinari P, Pallaoro M, Foti C, Talamo F, Orsatti L, Steinkühler C, Brancolini C. PP2A regulates HDAC4 nuclear import. *Mol Biol Cell* 2008; **19**: 655-667
- 42 **Illi B**, Dello Russo C, Colussi C, Rosati J, Pallaoro M, Spallotta F, Rotili D, Valente S, Ragone G, Martelli F, Biglioli P, Steinkühler C, Gallinari P, Mai A, Capogrossi MC, Gaetano C. Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. *Circ Res* 2008; **102**: 51-58
- 43 **Zhang X**, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE, Seto E. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. *Genes Dev* 2005; **19**: 827-839
- 44 **Togi S**, Kamitani S, Kawakami S, Ikeda O, Muromoto R, Nanbo A, Matsuda T. HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A. *Biochem Biophys Res Commun* 2009; **379**: 616-620
- 45 **Hu JH**, Chen T, Zhuang ZH, Kong L, Yu MC, Liu Y, Zang JW, Ge BX. Feedback control of MKP-1 expression by p38. *Cell Signal* 2007; **19**: 393-400
- 46 **Kinney CM**, Chandrasekharan UM, Yang L, Shen J, Kinter M, McDermott MS, DiCorleto PE. Histone H3 as a novel substrate for MAP kinase phosphatase-1. *Am J Physiol Cell Physiol* 2009; **296**: C242-C249
- 47 **Musikacharoen T**, Yoshikai Y, Matsuguchi T. Histone acetylation and activation of cAMP-response element-binding protein regulate transcriptional activation of MKP-M in lipopolysaccharide-stimulated macrophages. *J Biol Chem* 2003; **278**: 9167-9175
- 48 **Gómez-Cambronero L**, Camps B, de La Asunción JG, Cerdá M, Pellín A, Pallardó FV, Calvete J, Sweiry JH, Mann GE, Viña J, Sastre J. Pentoxifylline ameliorates cerulein-induced pancreatitis in rats: role of glutathione and nitric oxide. *J Pharmacol Exp Ther* 2000; **293**: 670-676
- 49 **Pereda J**, Sabater L, Cassinello N, Gómez-Cambronero L, Closa D, Folch-Puy E, Aparisi L, Calvete J, Cerdá M, Lledó S, Viña J, Sastre J. Effect of simultaneous inhibition of TNF-alpha production and xanthine oxidase in experimental acute pancreatitis: the role of mitogen activated protein kinases. *Ann Surg* 2004; **240**: 108-116
- 50 **Sato T**, Otaka M, Odashima M, Kato S, Jin M, Konishi N, Matsushashi T, Watanabe S. Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats. *Biochem Biophys Res Commun* 2006; **346**: 339-344
- 51 **Haddad JJ**, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. *J Pharmacol Exp Ther* 2002; **300**: 559-566
- 52 **Sandoval J**, Escobar J, Pereda J, Sacilotto N, Rodriguez JL, Sabater L, Aparisi L, Franco L, López-Rodas G, Sastre J. Pentoxifylline prevents loss of PP2A phosphatase activity and recruitment of histone acetyltransferases to proinflammatory genes in acute pancreatitis. *J Pharmacol Exp Ther* 2009; **331**: 609-617
- 53 **Chen TH**, Kao YC, Chen BC, Chen CH, Chan P, Lee HM. Dipyrdamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells. *Eur J Pharmacol* 2006; **541**: 138-146
- 54 **Cao W**, Bao C, Padalko E, Lowenstein CJ. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. *J Exp Med* 2008; **205**: 1491-1503

S- Editor Li LF L- Editor Lutze M E- Editor Yang C



ACKNOWLEDGMENTS

Acknowledgments to reviewers of World Journal of Gastrointestinal Pharmacology and Therapeutics

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Gastrointestinal Pharmacology and Therapeutics*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Reidar Fossmark, MD, PhD, Department of Gastroenterology and Hepatology, St. Olav's Hospital, Olav Kyrre's gate 17, Trondheim N-7006, Norway

Alessandro Granito, MD, Dipartimento di Medicina Clinica, Medicina Interna Bolondi, S. Orsola-Malpighi Hospital, Padiglione 2, Via Albertoni 15, 40138, Italy

Dimitrios Papandreou, Assistant Professor, 2nd Department of Pediatrics, Aristotle University of Thessaloniki, Ahepa Gen-

eral Hospital, Thessaloniki 54622, Greece

Martin J Ronis, Professor, Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Arkansas Children's Nutrition Center, 15 Children's Way, Little Rock, AR 72202, United States

Martin Alexander Storr, PD, Division of Gastroenterology, Health Science Center, 3280 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada

Ilker Tasci, MD, Associate Professor, Department of Internal Medicine, Gulhane School of Medicine, Etlik 06018, Ankara, Turkey

Takayuki Yamamoto, MD, PhD, Inflammatory Bowel Disease Center, Yokkaichi Social Insurance Hospital, 10-8 Hazuyamacho, Yokkaichi, Mie 510-0016, Japan

Angelo Zullo, MD, Department of Gastroenterology and Digestive Endoscopy, "Nuovo Regina Margherita" Hospital, Via E. Morosini 30, Rome 00153, Italy



Meetings

Events Calendar 2010

January 15-16, 2010
AGA Clinical Congress of
Gastroenterology and Hepatology
Las Vegas, United States
<http://www.gilearn.org/clinicalcongress>

February 4, 2010
New Developments in Pain Therapy
sponsored by the Swiss Society of
Pharmacology and Toxicology
Bern, Switzerland
<http://pharmacology.unibe.ch/SSPT2010>

February 5-9, 2010
Cancer Genomics, Epigenomics
& the Development of Novel
Therapeutics
Waikoloa, United States

February 7-10, 2010
53rd Annual Meeting of the Western
Pharmacology Society
San Diego, United States
<http://www.medicine.nevada.edu/wps/annualmeeting.html>

February 25, 2010
Multidisciplinary management of
acute pancreatitis symptoms
London, United Kingdom
<http://www.rsm.ac.uk/academ/pancreatitis10.php>

March 16-18, 2010
83rd Annual Meeting of the Japanese
Pharmacological Society
Osaka, Japan
http://www2.convention.co.jp/83jps/english/english_top.html

March 17-20, 2010
Annual Meeting of the American
Society for Clinical Pharmacology
and Therapeutics
Atlanta, United States
<http://www.ascpt.org/annualmeeting2010/index.cfm>

March 23-25, 2010
51st Annual Meeting of the German
Society for Experimental and Clinical
Pharmacology and Toxicology
Mainz, Germany
<http://www.pharmakologie.uni-mainz.de/JTG/JTG.html>

March 25-28, 2010
20th Conference of the Asian Pacific
Association for the Study of the
Liver
Beijing, China

<http://www.apasl2010beijing.org/en/index.aspx>

May 15, 2010
Digestive Disease Week 2010
New Orleans, United States
<http://www.ddw.org/>

June 2-4, 2010
Annual meeting of the Canadian
Society of Pharmacology and
Therapeutics
Toronto, Canada
<http://www.pharmacologycanada.org>

July 16-17, 2010
WorldPharma2010 Satellite Meeting:
The role of clinical pharmacology
in therapeutic drug monitoring and
clinical pharmacogenetics
Copenhagen, Denmark

July 17-23, 2010
16th World Congress on Basic
and Clinical Pharmacology
(WorldPharma2010)
Copenhagen, Denmark
<http://www.WorldPharma2010.org>

September 12-14, 2010
39th Annual Meeting of the
American College of Clinical
Pharmacology

Baltimore, United States
<http://www.accp1.org>

September 23-26, 2010
The 1st World Congress on
Controversies in Gastroenterology &
Liver Diseases
Prague, Czech

October 15-20, 2010
ACG 2010: American College of
Gastroenterology Annual Scientific
Meeting
San Antonio, United States

October 20-23, 2010
Australian Gastroenterology Week
Melbourne, Australia
<http://www.gesa.org.au/agw.cfm>

November 11-12, 2010
20th Neuropharmacology
Conference co-organized by the
Nomenclature Committee of
IUPHAR (NC-IUPHAR): Receptor
Structure and Drug Design
San Diego, United States
<http://www.neuropharmacology-conference.elsevier.com>

November 13-14
Case-Based Approach to the
Management of Inflammatory Bowel
Disease
San Francisco, United States



Instructions to authors

GENERAL INFORMATION

World Journal of Gastrointestinal Pharmacology and Therapeutics (*World J Gastrointest Pharmacol Ther*, *WJGPT*, online ISSN 2150-5349, DOI: 10.4292), is a bimonthly, open-access (OA), peer-reviewed journal supported by an editorial board of 188 experts in gastrointestinal pharmacology and therapeutics from 36 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJGPT* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJGPT* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJGPT* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their

wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

The major task of *WJGPT* is to rapidly report the most recent results in basic and clinical research on gastrointestinal pharmacology & therapeutics, including the effects of drugs on the gastrointestinal, pancreatic and hepatobiliary systems, particularly with relevance to clinical practice. *WJGPT* accepts papers on the following aspects related to gastroenterology or hepatology: (1) Clinical pharmacological research articles on specific drugs, concerning with pharmacodynamics, pharmacokinetics, toxicology, clinical trial, drug reactions, drug metabolism and adverse reaction monitoring, etc; (2) Research progress of clinical pharmacology; (3) Introduction and evaluation of new drugs; (4) Experiences and problems in applied therapeutics; (5) Research and introductions of methodology in clinical pharmacology; and (6) Guidelines of clinical trial. Specifically, this journal welcome research and review articles associated with both Western medicine and Chinese herbs as well as their combinations in basic and clinical application.

The columns in the issues of *WJGPT* will include: The columns in the issues of *WJGPT* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in gastrointestinal pharmacology & therapeutics; (9) Brief Articles: To briefly report the novel and innovative findings in gastrointestinal pharmacology & therapeutics; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJGPT*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of gastrointestinal pharmacology & therapeutics; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in gastrointestinal pharmacology & therapeutics.

CSSN

ISSN 2150-5349 (online)

Published by

Beijing Baishideng BioMed Scientific Co., Ltd.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for

Instructions to authors

publication become the permanent property of Beijing Baishideng BioMed Scientific Co., Ltd, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the International Committee of Medical Journal Editors to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2150-5349/office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2150-5349/g_info_20100315084234.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjgpt@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the

data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Telephone: +86-10-59080039 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJGPT*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles, rapid communication and case reports, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/2150-5349/g_info_20100315085528.htm.

Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures.

This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with

the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer

Instructions to authors

disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/EID/eid.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 $24.5 \mu\text{g/L}$; CO_2 volume fraction, 50 mL/L CO_2 , not 5% CO_2 ; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/2150-5349/g_info_20100315090437.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJGPT*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos, copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

Editorial Office

World Journal of Gastrointestinal Pharmacology and Therapeutics

Editorial Department: Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
E-mail: wjgpt@wjgnet.com
<http://www.wjgnet.com>
Telephone: 0086-10-85381891
Fax: 0086-10-85381893

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2150-5349/g_info_20100315090344.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2150-5349/g_info_20100315090255.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJGPT will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

Authors of accepted articles must pay a publication fee.

EDITORIAL, TOPIC HIGHLIGHTS, BOOK REVIEWS and LETTERS TO THE EDITOR are published free of charge.